Risk factors for Peyronie's disease: a case-control study.

City Department for Skin and Venereal Diseases, School of Medicine, Belgrade University, Belgrade, Serbia and Montenegro.
BJU International (Impact Factor: 3.05). 04/2006; 97(3):570-4. DOI: 10.1111/j.1464-410X.2006.05969.x
Source: PubMed

ABSTRACT To test some hypotheses about risk factors for Peyronie's disease (PD).
In a case-control study, 82 patients with PD, consecutively diagnosed at the first author's institution, were compared with 246 men visiting the same institution for dermatological diseases. Univariate and multivariate logistic regression analyses were used to assess the data.
From the multivariate logistic regression analysis the risk factors for PD were: a history of genital and/or perineal injuries, transurethral prostatectomy, cystoscopy, diabetes mellitus, hypertension, lipoma, propranolol in therapy, Dupuytren's contracture in the medical history, ever having smoked, alcohol consumption, fibromatous lesions of the genital tract of the partner, and surgical intervention on the genital tract of the partner.
The results of the present study are in line with the hypothesis that, in addition to genetic predisposition, trauma of the penis and systemic vascular diseases are risk factors for PD. Smoking and alcohol consumption also seem to have some role in the development of the disease.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Peyronie's disease (PD) is due to a fibrotic plaque forms in the tunica albuginea layer of the penis. It is responsible of penile pain, angulation, and erectile dysfunction. Even though the aetiology remains unknown, the knowledge of the pathophysiology has evolved in recent years. Recent studies indicate that PD has prevalence of 3 to 9% in adult men. During the initial acute phase (6 to 18 months), the condition may progress, stabilize or regress in 20%. Therefore, a conservative treatment approach has been advocated. An initial discussion about evaluation, information, and reassurance is necessary in most cases. The most commonly employed oral therapies include tocopherol (vitamin E), and para-aminobenzoate (Potaba), which have failed to demonstrate efficiency. Intralesional injection therapies with interferon alpha-2B, verapamil are frequently used as a first-line treatment modality, and can provide an improvement in decreasing penile pain and penile curvature. Current literature has shown that extracorporeal shock wave lithotripsy was only active on the pain. Regarding penile curvature, there are discrepancies in the published series. The surgical approach is restricted to men unresponsive to nonoperative therapies (i.e., 10% of patients). In such cases, plication, grafting or even penile prosthesis implantation are conceivable management options.
    Progrès en Urologie 02/2010; 20(2):91-100. · 0.80 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper reports on the incidence, presentation, and aetiological factors of Peyronie's disease in a sexual centre over an 8 year period. Of approximately 13,000 male patients, 672 (5%) were diagnosed with Peyronie's disease. The mean age was 55.6 years. Presenting symptoms included penile curvature (82%), erectile dysfunction (66%), and a history of penile pain (47%). Where possible aetiological data were recorded, 37% (of 340) had been catheterised and 42% (of 257) had a history of penile trauma. Of those presenting with penile curvature, the majority (76.4%) had a dorsal curve and the commonest plaque site was the dorsal tunica albuginea. The incidence of erectile dysfunction, catheterisation, and penile trauma is higher than that reported in many studies. This is likely to be due to the specialist nature of the clinic and the variability of information in patient files.
    Sexuality and Disability 05/2002; 20(2):109-116. · 0.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Peyronie's disease (PD) is a chronic wound-healing disorder characterized by formation of fibrous inelastic scarring of the tunica albuginea resulting in a variety of penile deformities. In most cases, PD is accompanied by a physical and psychological impact. Xiaflex® is an injectable collagenase clostridium histolyticum (CCh) preparation consisting of a predetermined mixture of two distinct collagenases. Recently the US Food and Drug Administration (FDA) approved Xiaflex® for the nonsurgical treatment of men with PD with curvature of 30° or more and tangible scar tissue plaque in their penis.
    Therapeutic Advances in Urology 10/2014; 6(5):192-197.